A sponsor completes a Phase III trial with a positive primary endpoint. The database is locked, the clinical study report is filed, and the regulatory submission is in. Manuscript writing comes next. Six months later, two journals have rejected the draft. It now sits in a third journal’s review queue, and the lead author has […]
Read More →Singapore and Malaysia are the two most-cited APAC markets for sponsors planning Phase II clinical trials outside Japan, India, and Australia. Both have strong regulatory frameworks, experienced investigator pools, and GCP-compliant site infrastructure. Because they are close enough in quality to require a deliberate choice, and different enough in cost and timelines for that choice […]
Read More →The Asia-Pacific region is home to a diverse array of traditional medicinal practices. The region is also rich in a large and diverse population. This diversity includes genetic variations, dietary patterns, environmental factors, and disease profiles, which makes trial results more applicable across global populations. Moreover, the growth of research facilities presents opportunities for sponsors […]
Read More →India is emerging rapidly as a global research and development hub for nutraceuticals. The country conducts nutraceutical clinical trials at lower costs while ensuring that the quality meets international standards. Nutraceutical clinical studies in India follow a regulated pathway, requiring approvals from both an Ethics Committee and the Central Drugs Standard Control Organization (CDSCO). It […]
Read More →Effective cost management serves as a way to overcome budget challenges in clinical trials. A proper understanding of the key cost factors that emerge throughout the study lifecycle helps to mitigate such challenges. Factors such as patient recruitment, regulatory compliance, site management, and data collection each contribute significantly to the total expenditure. When the cost […]
Read More →Protocol deviations for Visual Function Assessments (VFAs) in ophthalmology trials can affect the accuracy and reliability of outcomes. A VFA measures an individual’s functional or practical visual capabilities. This is in contrast to a standard eye exam, which includes a series of tests to measure real-world visual skills. VFAs perform both quantitative and qualitative assessments […]
Read More →In the drug development process, delaying the launch of a successful drug can result in lost sales. Early engagement to kickstart the clinical phase plays a key role in accelerating clinical trials and ultimately increasing revenue by providing earlier market access before competitors. Moreover, being the first to market a drug remains crucial for companies […]
Read More →Site engagement plays a key role in the success of clinical trials. Starting engagement at the right time and managing it well can make the trial process easier and more efficient. Using engagement strategies from the planning stage to post-trial collaboration helps overcome challenges like patient recruitment, ensures compliance, and improves data quality. This approach […]
Read More →The success of any clinical trial hinges on meticulous planning, starting with the careful identification of red flags in site selection to effectively avoid pitfalls before the trial starts. A poorly selected site can lead to costly delays, data inaccuracies, and regulatory complications, ultimately jeopardizing the trial’s objectives. Addressing these challenges early in the process […]
Read More →Pharmacokinetics (PK) analysis and statistical methods are fundamental to the Bioavailability (BA) and Bioequivalence (BE) research process. PK analysis helps understand the drug’s absorption, distribution, metabolism, and excretion (ADME) in the body. At the same time, statistical methods assess whether the drug formulations under study are equivalent in terms of their therapeutic effects. Together, these […]
Read More →